Medical Device Validation & Verification Market: as the FDA's Quality Management System Regulation reaches full enforcement and folds ISO 13485-aligned process validation directly into every US device manufacturer's quality system, validation and verification providers with the broadest accredited testing scope across geographies are converting a single compliance deadline into a multi-year global capacity expansion cycle, so laboratory footprint breadth is becoming as commercially decisive as individual test turnaround time.

The global medical device validation and verification market size was USD 6.84 Billion in 2025 and is expected to register a revenue CAGR of 9.4% during the forecast period.Market revenue growth is driven by factors such as the FDA's Quality Management System Regulation expanding process validation requirements for all US manufacturers, IEC 62304 software lifecycle standard requirements driving software validation demand, and geographic expansion of accredited V&V laboratory infrastructure into Asia Pacific.The first driving factor is the FDA's Quality Management System Regulation harmonizing 21 CFR Part 820 with ISO 13485:2016. The QMSR's process validation requirements mandate documented procedures for process validation, monitoring, and revalidation triggers for all processes where output cannot be fully verified by subsequent inspection alone.The second driving factor is IEC 62304 software lifecycle standard requirements driving software validation demand for the growing Software as a Medical Device and connected device categories. From 2020 to 2024, the FDA oversaw nearly 4,000 medical device recalls with validation failures among the leading root causes.The third driving factor is geographic expansion of accredited V&V laboratory infrastructure into Asia Pacific, extending testing capacity closer to the region's growing medical device manufacturing base.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single QMSR compliance deadline forces every affected manufacturer's validation programme investment into the same narrow window, which converts a regulatory enforcement date into concentrated demand for V&V providers with the accredited capacity to absorb that surge.Once the QMSR enforcement date approaches, manufacturers that have not already completed process validation documentation face a fixed deadline rather than a flexible internal project timeline, so V&V providers with the broadest accredited laboratory capacity capture a disproportionate share of the resulting compliance-driven demand surge simply by having the throughput to absorb clients who delayed until the deadline forced action.As a result, demand and revenue share are concentrating around V&V providers with the broadest accredited multi-geography laboratory capacity, that hold the deepest QMSR and IEC 62304 compliance expertise, and the forecast tilts toward these capacity-scaled providers rather than smaller regional specialists without comparable throughput.For instance, in February 2025, TÜV SÜD launched an advanced validation and verification laboratory in Singapore offering comprehensive EMI/EMC, mechanical, and biological testing services for the Asia Pacific medical device industry, adding accredited regional capacity ahead of the QMSR's February 2026 enforcement date and the parallel EU MDR compliance demand already driving European manufacturer validation spend.These are some of the key factors driving revenue growth of the market.

Because comprehensive process validation, software V&V, and design verification programmes require substantial capital investment relative to early-stage manufacturer budgets, this creates commercial pressure to defer comprehensive validation until regulatory submission timelines require it.

Skilled workforce shortages are a second constraint, since validation engineers with deep expertise in QMSR, IEC 62304, and ISO 14971 methodology are in short supply relative to growing demand, extending project timelines at high-volume V&V providers.

Revalidation burden is a third constraint, as any change to a validated process, software version, or device design can trigger a full or partial revalidation requirement, adding ongoing cost across the commercial life of the validated device or process.

These factors substantially limit medical device validation and verification market growth over the forecast period.

The clearest driver of demand is the compliance deadline itself, which converts an ongoing best-practice recommendation into a binding enforcement date with adulteration consequences for non-compliance. A manufacturer only accelerates validation investment ahead of schedule if the regulatory consequence of missing the deadline is severe enough to override competing budget priorities, and under the QMSR, failure to comply means devices are deemed adulterated by the FDA, a consequence serious enough to compress validation programme timelines across the industry simultaneously. The QMSR's process validation requirements, specified in 21 CFR Part 820 as aligned with ISO 13485:2016 Section 7.5.6, mandate documented procedures for process validation including monitoring and control methods, data analysis tools, and revalidation triggers for all processes where output cannot be fully verified by subsequent inspection or testing alone. From 2020 to 2024, the FDA oversaw nearly 4,000 medical device recalls in the US with validation failures among the leading root causes, confirming that inadequate validation creates substantial commercial risk that the QMSR is specifically designed to reduce. The effect on the market is that V&V demand is compressing into the period immediately surrounding the February 2026 enforcement date, rewarding providers with the accredited capacity to absorb clients who delayed validation investment until the deadline forced action. These are some of the key factors driving revenue growth of the market.

The second driver is the structural expansion of validation scope beyond conventional hardware processes into software lifecycle management as an increasing share of new device submissions include software components. A software-driven device only achieves regulatory clearance if its software lifecycle documentation meets IEC 62304 requirements, and as SaMD and AI/ML-enabled devices represent a growing share of new device submissions, V&V providers without dedicated software validation expertise increasingly cannot serve the full breadth of manufacturer demand across both hardware and software validation scope. The FDA's Predetermined Change Control Plan framework, allowing manufacturers to pre-specify future AI/ML model modifications within an approved change protocol, is adding a new validation dimension specifically for adaptive AI-enabled devices that conventional software V&V methodology was not originally designed to address. Intertek expanded its US facility to include specialized cybersecurity validation services for AI-powered medical devices, addressing the growing SaMD and connected device software validation market with dedicated capability beyond conventional IEC 62304 compliance testing alone. The effect on the market is that software V&V is becoming a distinct, fast-growing service line requiring specialised expertise that is increasingly differentiating V&V providers from one another beyond conventional hardware process validation capability alone. These are some of the key factors driving revenue growth of the market.

“From 2020 to 2024, the FDA oversaw nearly 4,000 medical device recalls in the US with validation failures among the leading root causes, confirming the commercial risk the QMSR's February 2026 enforcement deadline is specifically designed to reduce.”

However, the medical device validation and verification market faces severe adoption constraints from high comprehensive validation programme costs, skilled workforce shortages, and ongoing revalidation burden.

Because comprehensive process validation, software V&V, and design verification programmes require substantial capital investment relative to early-stage manufacturer budgets, this creates commercial pressure for smaller manufacturers to defer comprehensive validation until regulatory submission timelines require it, concentrating premium V&V spend among better-capitalised manufacturers.

Skilled workforce shortages compound this, since validation engineers with deep expertise in QMSR, IEC 62304, and ISO 14971 methodology are in short supply relative to growing demand, extending project timelines and qualification bottlenecks at high-volume V&V providers.

Revalidation burden is the third constraint, as any change to a validated process, software version, or device design can trigger a full or partial revalidation requirement, adding ongoing cost across the commercial life of the validated device or process, so the total cost of validation compliance does not end at initial market clearance.

These factors substantially limit medical device validation and verification market growth over the forecast period.

Based on service, the global medical device validation and verification market is segmented into process validation, design verification, software V&V, and sterilization validation. Process validation holds the largest revenue share, because QMSR compliance requirements apply broadly across virtually every US medical device manufacturing operation regardless of device class or therapeutic area. Software V&V is expected to register the fastest revenue growth rate over the forecast period, driven by IEC 62304 requirements and the FDA's Predetermined Change Control Plan framework expanding validation scope for AI/ML-enabled devices.

Based on device type, the global medical device validation and verification market is segmented into active medical devices, Software as a Medical Device, and IVD devices. Active medical devices hold a significantly large revenue share, reflecting the breadth of implantable and capital equipment device categories requiring comprehensive process and design validation. Software as a Medical Device is expected to register the fastest revenue growth rate, driven by the growing volume of AI diagnostic and connected device submissions requiring specialised software lifecycle validation at providers including Intertek and TÜV SÜD.

Based on therapeutic area, the global medical device validation and verification market is segmented into cardiovascular, neurology, orthopedics, general surgery, and ophthalmology and other. Cardiovascular holds the largest revenue share, reflecting the complexity and regulatory scrutiny applied to pacemaker, stent, and ICD validation programmes given their Class III risk classification. Neurology is expected to register the fastest revenue growth rate, driven by expanding deep brain stimulation and cochlear implant device validation demand as neuromodulation device categories grow.

Based on regional analysis, the medical device validation and verification market in North America accounted for largest revenue share in 2025 at approximately 42.3% of global market revenue. The United States leads because the QMSR's February 2026 enforcement deadline creates a binding compliance requirement for every US device manufacturer, and because the country hosts the largest concentration of accredited V&V laboratory capacity among TÜV SÜD, SGS, Eurofins, and Intertek. The QMSR's adulteration consequence for non-compliance creates a uniquely severe regulatory risk profile in the United States relative to other major device markets, reinforcing sustained validation investment ahead of the enforcement date. The concentration of accredited V&V laboratory capacity in the United States also means new validation methodologies, including AI/ML-specific software validation approaches, are often developed and piloted domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Switzerland represent the four largest national markets, with TÜV SÜD and SGS anchoring the region's V&V laboratory infrastructure. EU MDR's ongoing notified body conformity assessment requirements sustain steady European validation demand, but notified body capacity constraints create submission timeline bottlenecks that outsourced V&V capacity alone cannot fully resolve. The result is steady rather than rapid growth, shaped more by notified body throughput constraints than by underlying validation demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period, driven by China, Japan, South Korea, and Singapore's expanding medical device manufacturing base and growing accredited laboratory infrastructure. TÜV SÜD's February 2025 Singapore laboratory launch reflects the broader pattern of European TIC providers extending accredited V&V capacity closer to Asia Pacific's growing device manufacturing base. This leaves more room for growth than in the more mature North American and European V&V markets, where manufacturer-provider relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with V&V laboratory access concentrated at private facilities serving ANVISA and COFEPRIS submission requirements. Iran-US sanctions continue to disrupt freight and import costs for the specialised test instrumentation and calibration standards that Latin American V&V laboratories depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed equipment costs and slowing accredited laboratory capacity expansion beyond the region's main testing centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new demand for accredited validation and verification infrastructure. The UAE is the most established market on the continent for accredited V&V laboratory capacity, while the Gulf states more broadly are still building specialised validation infrastructure largely from scratch.